Radioligand Therapy Becoming Increasingly Preferred in Advanced Cancer Care

Radioligand therapy is an innovative method to treat cancer, wherein radiation is targeted at cancer cells, aiming to impact them as much as possible. A radioligand is comprised of two parts: a ligand and radioisotope. Ligands can detect cancer cells with specific surface molecules, whereas the radioisotope emits radiation to kill them.

Special nuclear reactors are utilized to produce these radioisotopes, which are shipped to the production facility where the cell-targeting compound is bonded with them. The usage of these materials in imaging is majorly in PET and SPECT imaging, which has drastically improved cancer diagnosis rates, thus ensuring more people receive the appropriate care.

The rise in cancer research grants, to find out effective treatments, and the increasing demand for more-effective drugs proliferate the adoption of this therapy. Therefore, in 2021, the radioligand therapy market valued $7,785.6 million; it is expected to advance at a CAGR of 5.9% from 2021 to 2030, to hit the $13,073.9 million mark by 2030, ascribed to the massive usage of FDA-approved drugs that have low side-effects.

Therefore, this treatment is already widely being adopted in the U.S., also attributed to the government initiatives to improve cancer care and the rising number of cancer hospitals and research centers in major cities. For example, U.S. President Joe Biden has announced the rejuvenation of the Cancer Moonshot Program with the new goal of decreasing the death rate caused by cancer in the next 25 years. The availability of advanced oncologic practices, as a result of the R&D funding provided under such government initiatives, will result in the increasing adoption of radioligand cancer therapy.

Hence, several pharmaceutical companies are focusing on R&D in this field, considering its high potential for cancer diagnosis and treatment. For example, the FDA approved Pluvicto by Novartis as a targeted treatment for PSMA-positive metastatic castration-resistant prostate cancer that progresses, in March 2022. Such moves not only allow for better cancer care but also enable pharma and biotech firms to improve their standing in the domain.

Therefore, radioligand therapy is expected to be extensively adopted to treat prostate and other types of cancers and non-cancer conditions.

Browse Full Report Radioligand Therapy Market Segmentation & Strategy